Our leadership
Learn more
Polly is a trainee in the Hong Kong office. She joined the firm in 2024.
Experience
Representative matters
Representative matters
Acting for eLong, Inc., a wholly-owned subsidiary of Tongcheng Travel Holdings Limited (stock code: 0780) (“Tongcheng Travel”), as Offeror in its HK$1.42 billion (approximately US$183 million) voluntary conditional general cash offer for all the issued shares in Dida Inc. (stock code: 02559), a carpooling and mobility platform listed on the Main Board of the Hong Kong Stock Exchange. Tongcheng Travel is a leading online travel platform in China principally engaged in the provision of transportation ticketing, accommodation reservation and tourism-related services.
Advising Shanghai Fosun New Medicine Research Company Limited (“Fosun New Medicine”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 2196), in relation to its proposal for the pre-conditional privatisation of Shanghai Henlius Biotech, Inc. (“Henlius”, stock code: 2696) by Fosun New Medicine as an offeror by way of merger by absorption of Henlius. The proposal valued Henlius at HK$13.37 billion (US$1.71 billion).
Advising a Hong Kong listed company on the purchase of shares in two NASDAQ companies.
Representative Experience
Acting for eLong, Inc., a wholly-owned subsidiary of Tongcheng Travel Holdings Limited (stock code: 0780) (“Tongcheng Travel”), as Offeror in its HK$1.42 billion (approximately US$183 million) voluntary conditional general cash offer for all the issued shares in Dida Inc. (stock code: 02559), a carpooling and mobility platform listed on the Main Board of the Hong Kong Stock Exchange. Tongcheng Travel is a leading online travel platform in China principally engaged in the provision of transportation ticketing, accommodation reservation and tourism-related services.
Advising Shanghai Fosun New Medicine Research Company Limited (“Fosun New Medicine”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 2196), in relation to its proposal for the pre-conditional privatisation of Shanghai Henlius Biotech, Inc. (“Henlius”, stock code: 2696) by Fosun New Medicine as an offeror by way of merger by absorption of Henlius. The proposal valued Henlius at HK$13.37 billion (US$1.71 billion).
Advising a Hong Kong listed company on the purchase of shares in two NASDAQ companies.
Credentials
Education
Education
- The Chinese University of Hong Kong, 2022, PCLL
- University of Cambridge, 2020, LL.B.